Sciences Press News Today

So primitively, reasoned the romantic kemerovo resident. He wanted to truly surprise his woman. Having finished his work on the farm and having celebrated the matter, he rode home on a stallion. Here is the surveillance camera footage. The rider took the animal by the throat and dragged him not only into the entrance, but also took him in the elevator to the fifth floor. The surprise man did not saddle the stallion the first time. But, judging by the photo already in the apartment, which was tak...

TORRANCE, Calif., Feb. 2, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Puerto...

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Dr. Niihara was the p

Emmaus Life Sciences Reports Q2 2023 Financial Results Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net... -Today at 03:28 pm- MarketScreener

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif., July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a leader in sickle cell disease treatment, today

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif., July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment,...

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...